Abstract
Introduction: Vasomotor symptoms (VMS) are common, with long lasting and debilitating effects on quality of life (QoL) during and after the menopause transition. There is an unmet need for safe and effective non-hormonal treatments for these symptoms. Hypothalamic KNDy neurons are central to the thermoregulatory dysfunction associated with VMS. They express Substance P (neurokinin [NK]-1R ligand) and NKB (NK-3R ligand) and are hypertrophied and hyperactive in oestrogen-deprived post-menopausal women. Elinzanetant is a dual NK-1 and NK-3 receptor antagonist. A prior Phase 2a study showed rapid and marked improvements in VMS in post-menopausal women and this study (SWITCH-1) was a Phase 2b double-blind, placebo-controlled, dose-finding trial which evaluated the optimal dose of elinzanetant for Phase 3 studies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
